Form 4: Day One Biopharmaceuticals Executive Sells 30,000 Shares Under 10b5-1 Plan
SEC Form 4 Filing
Day One Biopharmaceuticals' Head of R&D, Samuel C. Blackman, sold 30,000 shares of common stock at a weighted average price of $13.3113 per share.
Summary
- Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 30,000 shares of the company's common stock.
- The sale occurred on December 10, 2024, at a weighted average price of $13.3113 per share.
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 10, 2023.
- The shares were sold in multiple transactions with prices ranging from $13.14 to $13.49 per share.
- Mr. Blackman is the sole manager of the 2021 Blackman Family LLC and shares voting and dispositive power with his wife.
- He disclaims beneficial ownership of the shares held by the LLC except for his and his wife's pecuniary interest.
Sentiment
Score: 5
Explanation: The document reports a routine stock sale by an executive under a pre-arranged plan. It is a neutral event with no significant positive or negative implications.
Risks
- Executive stock sales can sometimes be perceived negatively by the market, potentially impacting investor sentiment.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies and are often part of pre-arranged trading plans to avoid accusations of insider trading. This sale by the Head of R&D is not unusual but is a routine disclosure.
Comparison to Industry Standards
- Rule 10b5-1 trading plans are a standard practice for executives at publicly traded companies to manage their personal finances while avoiding potential insider trading issues.
- The reported price range and weighted average price are typical for transactions of this nature.
- Similar sales are regularly reported by executives at comparable biotech companies.
Stakeholder Impact
- The stock sale may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the company's stock price.
Key Dates
| Date | Description |
|---|---|
| 2023-10-10 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2024-12-10 | Date of the stock sale by Samuel C. Blackman. |
| 2024-12-12 | Date of the filing of the Form 4. |
Keywords
Day One Biopharmaceuticals, stock sale, insider trading, Rule 10b5-1, Samuel C. Blackman, executive, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.